What can we learn from SOCRATES: more questions than answers? [PDF]
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core +1 more source
Aim:The imbalance between production of reactive oxygen species and antioxidant defense determines the degree of oxidative toxicity and severity of subsequent myocardial damage.We aimed to evaluate the anti-oxidative effects of neprilysin and angiotensin
Duygun Altıntaş Aykan +4 more
doaj +1 more source
Associations of Neprilysin and Its Coding Gene Variation With Hypertension in Chinese Adults. [PDF]
ABSTRACT Neprilysin (NEP) degrades several vasoactive peptides and may contribute to blood pressure maintenance. This study aims to examine the associations between serum NEP levels and variants at its coding gene and hypertension in a general Chinese population.
Hu J +14 more
europepmc +2 more sources
Impacts of the combined exposure to seawater acidification and arsenic on the proteome of Crassostrea angulata and Crassostrea gigas [PDF]
Proteomic analysis was performed to compare the effects of Arsenic (As), seawater acidification (Low pH) and the combination of both stressors (Low pH + As) on Crassostrea angulata and Crassostrea gigas juveniles in the context of global environmental ...
Bebianno, Maria +6 more
core +1 more source
Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition
Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely. Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of ...
Sandeep Lahiry
doaj +1 more source
Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T. +11 more
core +3 more sources
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]
Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva +17 more
core +1 more source
INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY
The article is devoted to the innovative drug to treat chronic cardiac insufficiency – a combination of sakubitril neprilysin inhibitor and first type angiotension II receptor antagonist valsartan (sacubitril/valsartan).
N. A. Jaiani
doaj +1 more source
‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure [PDF]
The clinical syndrome of heart failure is one of the leading causes of hospitalisation and mortality in older adults. An association between cognitive impairment and heart failure is well described but our understanding of the relationship between the ...
Cannon, Jane A. +2 more
core +4 more sources
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig +15 more
core +1 more source

